Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2020 1
2021 2
2022 1
2023 5
2024 11
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean alani b (122 results)?
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
Wilkins D, Langedijk AC, Lebbink RJ, Morehouse C, Abram ME, Ahani B, Aksyuk AA, Baraldi E, Brady T, Chen AT, Chi H, Choi EH, Cohen R, Danilenko DM, Gopalakrishnan V, Greenough A, Heikkinen T, Hosoya M, Keller C, Kelly EJ, Kragten-Tabatabaie L, Martinón-Torres F, de Los Santos AHM, Nunes MC, Palomino MA, Papenburg J, Pernica JM, Richmond P, Stein RT, Tuffy KM, Verwey C, Esser MT, Tabor DE, Bont LJ; INFORM-RSV Study Group. Wilkins D, et al. Among authors: ahani b. Lancet Infect Dis. 2023 Jul;23(7):856-866. doi: 10.1016/S1473-3099(23)00062-2. Epub 2023 Mar 17. Lancet Infect Dis. 2023. PMID: 36940703
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).
Tuffy KM, Ahani B, Domachowske JB, Furuno K, Ji H, Madhi SA, Mankad VS, Hamrén UW, Villafana T, Wang Y, Kelly EJ, Wilkins D. Tuffy KM, et al. Among authors: ahani b. Vaccine. 2024 Oct 24;42(24):126276. doi: 10.1016/j.vaccine.2024.126276. Epub 2024 Sep 5. Vaccine. 2024. PMID: 39241352 Free article. Clinical Trial.
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials.
Ahani B, Tuffy KM, Aksyuk AA, Wilkins D, Abram ME, Dagan R, Domachowske JB, Guest JD, Ji H, Kushnir A, Leach A, Madhi SA, Mankad VS, Simões EAF, Sparklin B, Speer SD, Stanley AM, Tabor DE, Hamrén UW, Kelly EJ, Villafana T. Ahani B, et al. Nat Commun. 2023 Jul 19;14(1):4347. doi: 10.1038/s41467-023-40057-8. Nat Commun. 2023. PMID: 37468530 Free PMC article. Clinical Trial.
Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY).
Arbetter D, Gopalakrishnan V, Aksyuk AA, Ahani B, Chang Y, Dagan R, Esser MT, Hammitt LL, Mankad VS, Saez-Llorens X, Shen D, Leach A, Kelly EJ, Villafana T, Wilkins D. Arbetter D, et al. Among authors: ahani b. Clin Infect Dis. 2025 Oct 6;81(3):634-644. doi: 10.1093/cid/ciae596. Clin Infect Dis. 2025. PMID: 39656748 Free PMC article. Clinical Trial.
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
Maaske J, Sproule S, Falsey AR, Sobieszczyk ME, Luetkemeyer AF, Paulsen GC, Riddler SA, Robb ML, Rolle CP, Sha BE, Tong T, Ahani B, Aksyuk AA, Bansal H, Egan T, Jepson B, Padilla M, Patel N, Shoemaker K, Stanley AM, Swanson PA, Wilkins D, Villafana T, Green JA, Kelly EJ. Maaske J, et al. Among authors: ahani b. Front Immunol. 2023 Jan 13;13:1062067. doi: 10.3389/fimmu.2022.1062067. eCollection 2022. Front Immunol. 2023. PMID: 36713413 Free PMC article. Clinical Trial.
Factors influencing estimates of HIV-1 infection timing using BEAST.
Dearlove B, Tovanabutra S, Owen CL, Lewitus E, Li Y, Sanders-Buell E, Bose M, O'Sullivan AM, Kijak G, Miller S, Poltavee K, Lee J, Bonar L, Harbolick E, Ahani B, Pham P, Kibuuka H, Maganga L, Nitayaphan S, Sawe FK, Kim JH, Eller LA, Vasan S, Gramzinski R, Michael NL, Robb ML, Rolland M; RV217 Study Team. Dearlove B, et al. Among authors: ahani b. PLoS Comput Biol. 2021 Feb 1;17(2):e1008537. doi: 10.1371/journal.pcbi.1008537. eCollection 2021 Feb. PLoS Comput Biol. 2021. PMID: 33524022 Free PMC article.
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection.
Lewitus E, Sanders-Buell E, Bose M, O'Sullivan AM, Poltavee K, Li Y, Bai H, Mdluli T, Donofrio G, Slike B, Zhao H, Wong K, Chen L, Miller S, Lee J, Ahani B, Lepore S, Muhammad S, Grande R, Tran U, Dussupt V, Mendez-Rivera L, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Janes H, Gilbert PB, Gramzinski R, Vasan S, Robb ML, Michael NL, Krebs SJ, Herbeck JT, Edlefsen PT, Mullins JI, Kim JH, Tovanabutra S, Rolland M. Lewitus E, et al. Among authors: ahani b. Virus Evol. 2021 Jul 9;7(2):veab057. doi: 10.1093/ve/veab057. eCollection 2021. Virus Evol. 2021. PMID: 34532060 Free PMC article.
26 results